Company profileMixed portfolio#853 of 1,318 in Pakistan✓ No DRAP alerts

HAROON BROS

Mixed portfolio · 8 pharmaceutical brands of 8 registrations

Ranked #3 of 5 companies in Surgical Aids

8 registered products 8 pharmaceutical brands 8 distinct molecules 0 DRAP alerts
Part of this company's portfolio (“Eye”) is registered under a broad DRAP category rather than distinct molecules, so the molecule count understates its true range.

Company overview

8
registered products
8
pharmaceutical brands
8
distinct molecules
7
therapeutic classes
0
DRAP alerts

HAROON BROS is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 8 product registrations across 8 distinct molecules. Its portfolio is concentrated in Surgical Aids and Anti-Infective, Ophthalmologicals. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Eye3 brands
Ofloxacin1 brand
Ketotifen1 brand
Timolol1 brand

Therapeutic classes

Surgical Aids · 2Anti-Infective, Ophthalmologicals · 1Peripheral Vasodilators · 1Other Dermatological Preparations · 1Other Ophthalmologicals · 1Decongestants And Antiallergics · 1Antiglaucoma Preparations And Miotics · 1

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

VEGA PHARMACEUTICALS LTD.5 shared molecules
Sante (Private) Limited5 shared molecules
ALZA Pharma4 shared molecules
VALOR PHARMACEUTICALS4 shared molecules
INNVOTEK PHARMACEUTICALS3 shared molecules
KOBEC3 shared molecules

Get the full profile for HAROON

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.